Baker Bros. Advisors LP Chemo Centryx, Inc. Transaction History

Baker Bros. Advisors LP

$9.34 Billion
Q3 2024

Shares

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $13.5 Million - $24.1 Million	875,795 Added 95.52%	1,792,657 $44.4 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $15.9 Million - $27.9 Million	-714,404 Reduced 43.79%	916,862 $23 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $24.4 Million - $53.9 Million	1,330,071 Added 441.6%	1,631,266 $59.4 Million
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $3.97 Million - $5.97 Million	301,195 New	301,195 $5.15 Million
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $6.3 Million - $33.4 Million	-656,710 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $11.5 Million - $15.8 Million	-243,111 Reduced 27.02%	656,710 $40.7 Million
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $2.1 Million - $2.8 Million	-45,400 Reduced 4.8%	899,821 $49.3 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $3.33 Million - $5.61 Million	86,206 Added 10.04%	945,221 $54.4 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $3.93 Million - $6.09 Million	119,999 Added 16.24%	859,015 $34.5 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $3.62 Million - $21 Million	531,987 Added 256.96%	739,016 $29.2 Million
Q4 2018 Feb 13, 2019	SELL	$9.15 - $12.26 $1.89 Million - $2.54 Million	-207,000 Reduced 50.0%	207,029 $2.26 Million
Q1 2018 May 15, 2018	BUY	$5.9 - $14.99 $2.15 Million - $5.47 Million	364,965 Added 743.85%	414,029 $5.63 Million
Q3 2017 Nov 14, 2017	BUY	$6.5 - $10.69 $318,916 - $524,494	49,064	49,064 $364,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.